• Biotin-16-UTP: Precision RNA Labeling for Advanced Assays

  2026-05-15

  Biotin-16-UTP empowers researchers to generate high-yield, biotin-labeled RNA for robust detection, purification, and interaction studies. This optimized nucleotide streamlines in vitro RNA labeling, enabling reproducible insights in lncRNA biomarker discovery and RNA-protein mapping.

• Propranolol in Hypertension: Dose Response and Clinical Util

  2026-05-15

  This editorial examines the foundational evidence supporting propranolol as a first-line non-selective β-adrenergic receptor blocker for hypertension management. It highlights its efficacy, individualized dosing strategies, and pharmacodynamic considerations, providing essential context for both clinical and experimental applications.

• LY2109761: Deep Analysis of Dual TGF-β Inhibition in Preclin

  2026-05-14

  Explore the unique role of LY2109761, a potent TGF-β receptor type I and II dual inhibitor, in modulating cancer progression and radiosensitivity. This article delivers an in-depth, application-focused perspective distinct from prior content.

• Reserpine (N1867): Technical Guide for Neuropharmacology Wor

  2026-05-14

  Reserpine (SKU N1867) is a high-purity, well-characterized research compound for neurotransmitter depletion and antihypertensive mechanism studies. It is not suitable for diagnostic or therapeutic use, but provides reproducibility and precise control in neuropharmacology research workflows. Proper preparation, handling, and storage are crucial to maintain compound integrity and experimental consistency.

• Canonical Anti-Apoptotic Role of MCL-1 in Breast Cancer Cell

  2026-05-13

  This article reviews evidence showing that breast cancer cell survival depends on the canonical, anti-apoptotic function of MCL-1. The reference study demonstrates that targeting MCL-1, genetically or with selective inhibitors, induces apoptosis in established tumors, emphasizing the therapeutic rationale for MCL-1 inhibitors in apoptosis-focused cancer research.

• Lactate-Driven Ran Lactylation Orchestrates Astrocyte Polari

  2026-05-13

  This study uncovers a novel metabolic-epigenetic mechanism in which lactate-induced lactylation of Ran at lysine 123, regulated by SIRT1, promotes A2 astrocyte polarization after oxygen-glucose deprivation/reoxygenation. These findings illuminate the pathway's importance in spinal cord injury response and highlight new research targets for CNS repair strategies.

• HyperScript™ Reverse Transcriptase: Empowering Precision RNA

  2026-05-12

  Explore how HyperScript™ Reverse Transcriptase advances cDNA synthesis for qPCR and complex RNA templates, enabling precise RNA analysis critical for next-generation genetic therapies. This article uniquely bridges enzyme selection with cutting-edge assay design, grounded in recent translational research.

• SU5416 (Semaxanib): Strategic Angiogenesis Inhibition in Tra

  2026-05-12

  This article provides a deep-dive into SU5416 (Semaxanib) as a VEGFR2 inhibitor, outlining its mechanistic underpinnings, translational value in cancer and vascular research, and the evolving landscape of angiogenesis inhibitors. Leveraging recent advances in PAH biomarker discovery and referencing the latest workflows, we position SU5416 as a versatile tool for researchers aiming to bridge experimental rigor with clinical relevance.

• Pioglitazone: Mechanistic Leverage and Strategy for Translat

  2026-05-11

  This thought-leadership article explores how pioglitazone, a selective PPARγ agonist, empowers translational researchers to decode and modulate immunometabolic pathways in metabolic and inflammatory disease models. By synthesizing mechanistic evidence—especially recent advances in macrophage polarization and the STAT-1/STAT-6 axis—the piece offers actionable guidance for experimental design, assay optimization, and strategic model selection. The discourse is anchored in rigorous literature, including a newly published study on inflammatory bowel disease, and positions APExBIO's pioglitazone as a best-in-class research tool.

• Salinomycin: Polyether Ionophore Antibiotic for HCC Research

  2026-05-11

  Salinomycin is a polyether ionophore antibiotic with potent, mechanism-driven anti-cancer effects, especially in hepatocellular carcinoma (HCC) models. Its primary actions are inhibition of ABC drug transporters and the Wnt/β-catenin pathway, leading to reduced proliferation and apoptosis in cancer cells. High-purity preparations from APExBIO support reproducible, benchmarked workflows in preclinical oncology.

• Açaí Extracts: Cytotoxicity and Enzyme Induction in Hepatocy

  2026-05-10

  This study systematically examines the cytotoxicity and induction profile of various açaí (Euterpe oleracea) extracts in human hepatocytes, addressing their potential to modulate key drug-metabolizing enzymes and transporters. The findings show dose-dependent cytotoxicity for certain extracts but minimal risk for enzyme or transporter induction, underscoring the need for rigorous evaluation of botanical supplements in pharmacological contexts.

• Synthetic Lethality in MSI Colon Cancer via WRN Loss and p53

  2026-05-09

  This study elucidates the mechanism underlying synthetic lethality between Werner (WRN) helicase inhibition and mismatch repair deficiency in colorectal cancer. The authors demonstrate that p53 and its downstream effector PUMA mediate apoptosis upon WRN loss in microsatellite instability (MSI) colorectal cancers, highlighting WRN as a promising therapeutic target for p53-wildtype MSI CRCs.

• Protoporphyrin IX: Optimizing Photodynamic Workflows in Canc

  2026-05-09

  Protoporphyrin IX stands out for its unique duality as a heme biosynthetic intermediate and a potent photodynamic compound used in cancer diagnostics and therapy. This article delivers actionable workflow enhancements, troubleshooting strategies, and translational insights, leveraging APExBIO’s high-purity Protoporphyrin IX for robust, reproducible results.

• BGJ398 (NVP-BGJ398): Precision FGFR Inhibition in Translatio

  2026-05-08

  This thought-leadership article unpacks the mechanistic basis and strategic application of BGJ398 (NVP-BGJ398), a selective FGFR1/2/3 inhibitor, in oncology and developmental biology research. It bridges recent evidence on FGFR signaling, highlights translational workflow optimizations, and provides actionable guidance on leveraging BGJ398 for maximal impact in FGFR-driven malignancies research, referencing both foundational studies and real-world protocols.

• Amorolfine Hydrochloride: Bridging Cell Integrity and Antifu

  2026-05-07

  This thought-leadership article explores how Amorolfine Hydrochloride, a potent antifungal reagent from APExBIO, is redefining fungal infection research by integrating mechanistic insights into cell membrane disruption, ploidy stress, and antifungal resistance. Drawing on landmark studies in yeast cell biology and recent translational workflows, we provide actionable guidance for researchers aiming to strategically advance antifungal drug development. This article uniquely bridges emerging evidence on ploidy limits and membrane integrity, offering a roadmap for next-generation experimental design.

16331 records 1/1089 page Next 12345 下5页 Last page